Want to see TSE:AVCR full AI Analyst Report?
AVCR Stock Chart & Stats
C$0.05
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.05
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.05 - C$0.10
Previous CloseN/A
Volume151.36K
Average Volume (3M)51.37K
Market Cap
C$5.57M
Enterprise ValueC$6.88
Total Cash (Recent Filing)C$210.30K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding101,289,665
10 Day Avg. Volume29,762
30 Day Avg. Volume51,367
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)13.00
Price to Sales (P/S)9.49
P/FCF Ratio-5.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring POCT Platform And Pharmacy NetworkAvricore’s HealthTab platform and in-pharmacy POCT programs combine software, connectivity and program administration to generate recurring fees tied to participating sites and test volumes. This platform-service mix creates sticky customer relationships and scalable revenue per site as the network expands.
Very Low Financial LeverageThe company’s essentially zero-debt position reduces fixed financing costs and insolvency risk, preserving flexibility to pursue partnerships or incremental investment. Low leverage provides a structural cushion during cash-strained periods and limits interest burden as the business seeks to stabilize revenues.
Historically Healthy Gross MarginsReported ~44% gross margins through 2025 indicate favorable unit economics on tests and related services. If testing volumes and pricing recover, these margins support operating leverage and the potential to absorb SG&A and platform costs, improving the path to sustainable profitability.
Bears Say
Steep Revenue Decline (TTM)A ~73% TTM revenue decline erodes scale needed for platform economics and weakens network effects with pharmacy partners. This magnitude of top-line loss undermines fixed-cost coverage, worsens per-unit economics, and makes recovery and sustainable growth dependent on securing new programs or material volume restoration.
Renewed Negative Operating Cash FlowOperating cash flow turning negative and worsening increases reliance on external financing and raises dilution risk. Persistent cash burn limits the company’s ability to invest in sales, product development, or program rollout, constraining execution of its platform strategy over the next several quarters.
Large Losses And Eroding Equity BaseMaterial equity erosion alongside large net losses (net margin deeply negative) weakens the capital base and financial flexibility. Continued losses make dilutive financings or restructuring likely, reducing investor upside and limiting resources to scale the platform without external support.
Avricore Health News
AVCR FAQ
What was Avricore Health Inc.’s price range in the past 12 months?
Avricore Health Inc. lowest stock price was C$0.04 and its highest was C$0.10 in the past 12 months.
What is Avricore Health Inc.’s market cap?
Avricore Health Inc.’s market cap is C$5.57M.
When is Avricore Health Inc.’s upcoming earnings report date?
Avricore Health Inc.’s upcoming earnings report date is Sep 02, 2026 which is in 25 days.
How were Avricore Health Inc.’s earnings last quarter?
Currently, no data Available
Is Avricore Health Inc. overvalued?
According to Wall Street analysts Avricore Health Inc.’s price is currently Overvalued.
Does Avricore Health Inc. pay dividends?
Avricore Health Inc. does not currently pay dividends.
What is Avricore Health Inc.’s EPS estimate?
Avricore Health Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avricore Health Inc. have?
Avricore Health Inc. has 101,289,665 shares outstanding.
What happened to Avricore Health Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Avricore Health Inc.?
Currently, no hedge funds are holding shares in TSE:AVCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Avricore Health Inc.
Avricore Health Inc. operates within Canada, specializing in health data management and point-of-care technological solutions. Their primary offering is HealthTab, a precise, laboratory-quality diagnostic testing system designed for use in pharmacies. This enterprise maintains key alliances with prominent organizations such as Shoppers Drug Marts and Abbott. Established in 1996 and headquartered in Vancouver, Canada, the company previously operated as Vanc Pharmaceuticals Inc., adopting its current name, Avricore Health Inc., in October 2018.
Technical Analysis
BioMark Diagnostics
―
Telo Genomics Corp
―
StageZero Life Sciences Ltd
―
―
PanGenomic Health, Inc. Class A
―